Abstract
The clinical potency of anti-programmed death-ligand 1 (PD-L1) therapy in metastatic triple-negative breast cancer (TNBC) is modest primarily because of the intrinsic low immunogenicity and an immunosuppressive tumor microenvironment (TME). Photodynamic therapy (PDT), an inducer of immunogenic cell death (ICD), has the potential to enhance antitumor immune response and improve PD-L1 blockade efficacy. DTP, a novel photosensitizer developed previously, has demonstrated potent ROS-dependent photocytotoxicity, yet its immunomodulatory effects remain unexplored. This study investigated the induction of ICD and dendritic cell (DC) maturation following DTP-PDT in vivo and in vitro. A bilateral TNBC model was developed to assess the efficacy of DTP-PDT combined with α-PD-L1 therapy on untreated distant tumors and to explore its potential immunological mechanisms. The results showed that DTP-PDT effectively induced ICD, demonstrated by calreticulin membrane exposure, high mobility group box 1 protein release, and increased secretion of interferon-γ and tumor necrosis factor-α, resulting in DC maturation. The combination of DTP-PDT and α-PD-L1 significantly inhibited distant tumor growth. This effect was associated with increased CD8+ and CD4+ T cells infiltration, and reduced numbers of regulatory T cells, in the distant tumor and spleen. In conclusion, DTP-PDT enhanced TNBC sensitivity to α-PD-L1 by inducing ICD, and its combination withα-PD-L1 could remodel the immunosuppressive TME and enhance systemic immunity, resulting in a therapeutic effect against distant metastasis. This study provides experimental validation for a combined strategy of DTP-PDT and α-PD-L1, proposing a potential therapeutic approach for metastatic TNBC.
1 Introduction
Triple-negative breast cancer (TNBC) represents 15%–20% of breast cancer cases (Garrido-Castro et al., 2019) and demonstrates aggressive biological behavior, lack of therapeutic targets, and a tendency for early metastasis (Criscitiello et al., 2012; Leon-Ferre and Goetz, 2023). Current treatments for TNBC primarily include surgery, chemotherapy, and radiotherapy (Subhan, 2024). While these approaches are effective in early-stage TNBC, they offer limited success against metastatic TNBC (mTNBC) (Li Y. et al., 2022).
Cancer immunotherapy, which involves engineering immune cells to specifically target and eliminate tumors, has attracted widespread attention over the past decade, especially for metastatic cancers (Kennedy and Salama, 2020; Pham et al., 2021). In mTNBC, immune checkpoint inhibitors, particularly the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) blockade, have emerged as a key immunotherapeutic approach (Zhu et al., 2023). However, PD-L1 blockade monotherapy yields suboptimal outcomes even in PD-L1-positive patients, with objective response rates (ORR) of 40% and median response durations less than 12 months (Schmid et al., 2018; Cortes et al., 2020).
The limited efficacy of PD-L1 blockade is largely due to two main factors: the low immunogenicity characterized by insufficient tumor antigen release and presentation; and the “cold” immunosuppressive tumor microenvironment (TME) (Liu et al., 2023). To address these challenges, current research is focused on enhancing tumor immunogenicity and transforming the “cold” TME into a more immunogenic environment to improve responses to immunotherapy (Khosravi et al., 2024). Emerging evidence underscores that combination therapies targeting multiple stages of the cancer immune cycle may offer enhanced therapeutic efficacy of PD-L1 blockade (Meric-Bernstam et al., 2021). These strategies include chemotherapy, anti-angiogenic agents, immune modulators, and localized treatments such as radiotherapy and photodynamic therapy (PDT) (Zhu et al., 2021).
PDT is a localized treatment that functions by activating photosensitizer with specific wavelength light, triggering the production of reactive oxygen species (ROS) which induce tumor cell death (Agostinis et al., 2011). Compared to conventional therapies, PDT provides distinct benefits, including minimal invasiveness, low systemic toxicity, and high selectivity (Brown et al., 2004; Pham et al., 2021). Recent advancements have highlighted that certain photosensitizers not only eradicate tumors locally but can also induce the releases of tumor-associated antigens and damage-associated molecular patterns (DAMPs), thereby stimulating systemic antitumor immunity (Li Z. et al., 2022). Preclinical studies in melanoma (Li et al., 2025), lung (Zhao et al., 2023), and pancreatic cancer (McMorrow et al., 2025) models have demonstrated that combining this immunogenic effect with PD-L1 blockade can overcome therapeutic resistance and enhance systemic immune responses. Additionally, PDT disrupts endothelial structures and increases vascular permeability, improving the intratumoral delivery of α-PD-L1 antibodies (Bhandari et al., 2024). Some studies have also shown that PDT can upregulate PD-L1 and PD-1 expression on lymphocytes (Lobo et al., 2023)or downregulate PD-L1 on tumor cells (He et al., 2024). In clinical settings, the combination of PDT and PD-L1 blockade has been found to remodel antitumor immunity in gastric cancer patients by increasing cytotoxic T lymphocytes (CTLs) infiltration and suppressing regulatory T cell (Treg) activity, ultimately leading to improved overall survival outcomes (Yu et al., 2023). These findings highlight the potential of PDT-based combination strategies to transform the immunosuppressive TME and enhancing immunotherapy efficacy. However, conventional porphyrin-based photosensitizers, despite serving as the foundation for PDT due to their efficient light absorption capabilities (Arnaut, 2011), face significant challenges including limited water solubility, inadequate tumor specificity, and pronounced dark toxicity (Tian et al., 2020; Akbar et al., 2023; Yin et al., 2024).
To overcome these challenges, Professor Tianjun Liu’s team developed a novel porphyrin-based photosensitizer, Meso-5-[ρ-diethylene triamine pentaacetic acid-aminophenyl]−10,15,20-triphenyl-porphyrin (DTP). DTP demonstrates excellent water solubility and significant phototoxicity when irradiated with a 650 nm laser in various cancer cell lines, while exhibiting low dark toxicity (Chen et al., 2015; Chen et al., 2016; Chen et al., 2017; Chen et al., 2024). These properties make it a promising candidate for further investigation.
Building on the promising photodynamic properties of DTP and considering the potential of PDT to improve immunotherapeutic responses, this investigation was designed to assess the capacity of DTP-PDT to elicit antitumor immunity. Additionally, this study explores the synergistic effect and underlying mechanisms of combining DTP-PDT with PD-L1 inhibitors for the treatment of mTNBC (Figure 1).
FIGURE 1
2 Materials and methods
2.1 Photosensitizer and light source
The photosensitizer DTP was synthesized and provided by Prof. Tianjun Liu (Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College). The purity of DTP was over 98% by High Performance Liquid Chromatography. UV-Vis absorption profiling of DTP dissolved in dimethyl sulfoxide (DMSO) was performed on a UH5700 spectrophotometer (Hitachi, Japan). A 650-nm semiconductor laser (WSLS-650-500m-M-2; Wave Spectrum Laser Group Limited, China) via a columnar fiber was used in the in vivo and in vitro study, ensuring precise and controlled irradiation conditions. The energy density of the illuminated spot was quantified using a light power meter (Coherent Corp., PA, United States).
2.2 Cell culture
The murine 4T1 breast tumor cell line was sourced from the National Collection of Authenticated Cell Cultures (Chinese Academy of Sciences, Shanghai). Cells were cultured in RPMI 1640 medium containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (PS), under standard humidified incubation (37°C, 5% CO2).
2.3 In vitro ICD biomarker analysis
4T1 cells plated in confocal dishes underwent 24-h incubation with DTP (200 nM). Subsequently, cultures were irradiated (650 nm laser, 20 mW/cm2, 5 min) or maintained as non-irradiated controls. Post-treatment, cells were fixed in 4% paraformaldehyde (PFA) (15 min, RT), permeabilized in 0.1% Triton X-100 (high mobility group box 1 (HMGB1) detection only), and blocked with 1% bovine serum albumin. Primary antibodies include anti-calreticulin (CRT) (1:200, ABclonal, A1066) or anti-HMGB1 (1:200, Wanleibio, WL03023) were applied overnight (4°C), followed by Alexa Fluor 488-conjugated secondary antibody incubation (1.5 h, RT). Cells were counterstained with DAPI (5 min, RT) and specimens imaged by confocal laser scanning microscopy (CLSM).
2.4 Isolation and culture of bone marrow-derived dendritic cells (BMDCs)
Bone marrow was isolated from femurs and tibias of 5–7-week-old C57BL/6 mice. Following erythrocyte lysis (Beyotime, C3702), cells were suspended in RPMI 1640 medium supplemented with 10% heat-inactivated FBS, 1% PS, 20 ng/mL recombinant murine granulocyte-macrophage colony stimulating factor (GM-CSF), and 10 ng/mL recombinant murine Interleukin-4 (IL-4). Culture medium was replaced every 48 h. On day 7, loosely adherent BMDCs were harvested by gentle pipetting and centrifugation (450 × g, 5 min).
2.5 BMDCs maturation assessment
4T1 cells pretreated with phosphate-buffered saline (PBS) or DTP (12 h) received 650 nm laser irradiation (20 mW/cm2, 5 min). Then, BMDCs were co-cultured with DTP-PDT-treated 4T1 cells in Transwell® inserts (0.4 μm pore, Corning) to enable soluble mediator exchange while preventing direct contact. Lipopolysaccharide (LPS; 1 mg/L) was used as a positive control. Following a 24-h co-culture period, the BMDCs were collected, labeled with anti-CD11c-BV421 (BioLegend, 117343), anti-CD80-PE (BioLegend, 104707), and anti-CD86-APC (BioLegend, 105011), and then subjected to flow cytometric analysis.
2.6 Cytokine detection
Cell supernatants from the transwell experiment were collected for cytokine detection using enzyme-linked immunosorbent assay (ELISA) kits specific for mouse tumor necrosis factor-α (TNF-α) (Cloud-Clone, SEA133Mu) and mouse interferon-γ (IFN-γ) (Cloud-Clone, SEA049Mu), strictly adhering to the protocols provided by the manufacturer.
2.7 Animals
Female BALB/c mice, aged 6–8 weeks (body weight 18–20 g), were purchased from HFK Bioscience (Beijing, China). Animals were maintained in a specific pathogen-free facility, regulated at constant temperature (22 ± 1°C), humidity (50% ± 10%), and a 12-h light/dark cycle. All animal experiments strictly followed the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. The Institutional Animal Care and Use Committee of the Institute of Radiation Medicine, Chinese Academy of Medical Sciences approved all experimental procedures under Ethics Approval No. IRM/2-IACUC-2409-094.
2.8 Evaluation of antitumor efficacy in a bilateral 4T1 tumor model
For bilateral breast tumor establishment, 5 × 105 luciferase-transfected 4T1 (4T1-Luc) cells, suspended in 100 μL PBS, were first subcutaneously injected into the right flank to generate the primary tumor site. Once the primary tumor reached 60 mm3, a secondary challenge was developed by inoculating 1 × 105 cells into the contralateral (left) flank to form a distinct distant tumor. Tumor growth was determined using the formula: Volume = (width2 × length) × 0.5.
When the primary tumor volumes reached 80–100 mm3, mice were randomly allocated into four treatment groups (n = 16 per group): Model (100 μL saline, intravenous), α-PD-L1 (10 mg/kg α-PD-L1 (A2115, Selleck, United States), administered intraperitoneal every 3 days), PDT (intravenous 10 mg/kg DTP followed by 650 nm laser irradiation at 100 J/cm2), and PDT + α-PD-L1 (combined DTP-PDT and α-PD-L1). Tumor dimensions and individual body weights were monitored every other day. Tumor progression was assessed weekly using bioluminescence imaging (IVIS Lumina III, Caliper Life Sciences).
2.9 Immune profiling and cytokine analysis
To evaluate the immune response, tumors, lnguinal lymph nodes, serum, and spleens were collected using sterile procedures on day 8 post-treatment. Tumor and lymphoid tissues underwent mechanical dissociation to generate single-cell suspensions. Subsequent processing included red blood cell (RBC) lysis, filtration, and extensive washing steps. Cell viability was determined using the Zombie Aqua™ Fixable Viability Kit (Biolegend, 423101). To block nonspecific binding, cells were incubated with TruStain FcX™ (anti-mouse CD16/32) antibody (Biolegend, 101319). Cells were then stained with the following antibodies: anti-CD45 FITC (Biolegend, 103107), anti-CD11c BV421 (Biolegend, 117329), anti-CD80 PE, anti-CD86 APC, anti-CD3ε Percp-cy5.5 (Biolegend, 100327), anti-CD4 PE (Biolegend, 100511), anti-CD8a APC (Biolegend, 100711), and anti-Forkhead box protein P3 (FoxP3) BV421 (Biolegend, 126419), followed by flow cytometric analysis. Serum levels of TNF-α and IFN-γ were measured using specific mouse ELISA kits. Immunofluorescence staining was performed on the tumor sections using anti-CD8 and anti-FoxP3 antibodies.
2.10 Histopathological assessment via hematoxylin and eosin (H&E) staining
On day 21 post-treatment, tumors were resected and fixed in 4% PFA, paraffin-embedded, and sectioned at 4 µm thickness. Following deparaffinization in xylene and graded ethanol rehydration, sections were subjected to H&E staining to evaluate the pathological changes. Images were acquired on a Leica DMILLED microscope system (Leica Microsystems). Ten fields per section were randomly selected for microscopic observation and quantitative analysis.
2.11 Statistical analysis
Data are expressed as mean ± standard deviation (SD). Data normality was confirmed via Shapiro-Wilk tests. Homogeneity of variance was validated using Levene’s test. For non-normally distributed data, Kruskal-Wallis with Dunn’s post hoc was employed. Differences between two groups were assessed via Student’s t-test, while differences among three or more groups were assessed via one-way analysis of variance (ANOVA). Statistical significance was defined as *p < 0.05, **p < 0.01, and ***p < 0.001.
3 Results
3.1 Optical properties of DTP
The molecular structure of DTP is illustrated in Figure 2A. UV-Vis spectroscopy revealed the spectral profile of DTP, with the main peak at 420 nm and additional peaks at 516, 551, 592, and 647 nm (Figures 2B,C). While DTP exhibits a primary absorption peak at 420 nm, we specifically employed 650 nm laser irradiation during treatment to leverage its deeper tissue penetration capability in the red-light spectrum (Austin et al., 2021), following clinical PDT standards (Allison et al., 2024).
FIGURE 2
3.2 DTP-PDT induces ICD in vitro
After laser irradiation, 4T1 cells treated with DTP were subjected to immunofluorescence staining targeting HMGB1 and CRT to assess whether DTP-PDT could induce ICD. As shown in Figure 3A, the distribution of HMGB1 was found to be predominantly nuclear in PBS or DTP treated cells. In contrast, HMGB1 was released into the extracellular space in DTP-PDT-treated cells. As demonstrated in Figure 3B, the laser-treated group exhibited intense green fluorescence on the cell surface in comparison to the non-irradiated group, demonstrating considerably elevated levels of CRT exposure. These results suggest that DTP-PDT triggers HMGB1 release and CRT translocation, confirming the induction of ICD.
FIGURE 3
3.3 DTP-PDT triggers BMDCs maturation and cytokine release
BMDCs were co-cultured with DTP-PDT-treated 4T1 cells using the experimental design illustrated in Figure 4A. Following co-culture, BMDCs exhibited significant maturation, as evidenced by upregulated expression of co-stimulatory markers CD80 and CD86. As demonstrated in Figures 4B,C, DTP + Laser induced a significantly higher proportion of mature BMDCs (45.53% ± 4.12%) in comparison with PBS (21% ± 2.29%) and DTP (21.57% ± 2.20%) groups (p < 0.001).
FIGURE 4
Specifically, significant increases in the secretion of IFN-γ (p < 0.001, Figure 4D) and TNF-α (p < 0.05, Figure 4E) were observed in the DTP + Laser group compared to the PBS and DTP groups. These findings indicate that DTP-PDT effectively induces DAMP release, promotes DC maturation, and enhances the expression of pro-inflammatory cytokines, thereby initiating immune responses.
3.4 Anti-abscopal effect of DTP-PDT combined with α-PD-L1 therapy in bilateral 4T1 tumor model
To address the limited efficacy of α-PD-L1 monotherapy in TNBC, we assessed the potential of DTP-PDT-induced ICD to enhance α-PD-L1 therapy and improve systemic antitumor efficacy in the 4T1 breast cancer model (Figure 5A). In the α-PD-L1 monotherapy group, local and distant tumor growth showed no significant difference compared with the model group (Figures 5B, 6A,B). In contrast, DTP-PDT alone resulted in an 81.62% reduction in primary tumor weight (p < 0.001 vs. model and α-PD-L1), but only a 35.35% reduction in distant tumor weight (p > 0.05 vs. model and α-PD-L1), highlighting that PDT has a significant therapeutic effect on irradiated primary tumors but little effect on unirradiated distant tumors. Remarkably, combining DTP-PDT and α-PD-L1 demonstrated a significant abscopal effect, with 83.31% primary tumor regression (p < 0.001 vs. model and α-PD-L1) and 82.15% distant tumor suppression (p < 0.001 vs. model, p < 0.01 vs. α-PD-L1, p < 0.05 vs. PDT) (Figures 6C,D). Importantly, across all treatment groups, the body weight change revealed no significant difference which suggests that the combined strategy has a good tolerability (Figure 6E).
FIGURE 5
FIGURE 6
Following treatment, H&E staining was performed on the primary and distant tumor tissue to observe histopathological changes. Figure 6F illustrates that tumor cells in the model and α-PD-L1 groups, as well as distant tumors in the PDT group, exhibited tight cell arrangements with rounded nuclei and well-defined nucleoli. In contrast, tumors in the PDT + α-PD-L1 group and primary tumors in the PDT group, displayed extensive nuclear consolidation, nuclear fragmentation, and visible necrotic areas. These findings provide further evidence of the remarkable inhibitory effect of the combination therapy on primary and distant tumors.
Collectively, our findings suggest that DTP-PDT-induced tumor-specific immune responses may be effective in sensitizing tumors towards PD-L1 blockade, and combining DTP-PDT with PD-L1 blockade could be a promising approach in treating metastatic TNBC.
3.5 Combined therapy reprograms the local tumor immune microenvironment
The synergistic antitumor effects observed in the combination therapy prompted further investigation of its immunological mechanisms. In order to assess the immune response, we analyzed populations of immune cells in the lymph nodes, tumors, and spleens. In our study, DC maturation was evaluated by flow cytometry in tumor-draining lymph nodes. As shown in Figures 7A,B, the DTP-PDT and DTP-PDT+α-PD-L1 groups had a significantly higher percentage (15.8% and 21.8%, respectively) of mature DCs (CD45+CD11c+CD80+CD86+) compared to the model (8.29%) and α-PD-L1 (10.40%) groups (p < 0.001), indicating that PDT promotes DC maturation in vivo.
FIGURE 7
The analysis of tumor-infiltrating T cells was performed in distant tumors. DTP-PDT+α-PD-L1 group revealed a 9.8-fold and 6.9-fold increase in CD8+ and CD4+ T cells, respectively, compared to the model group, indicating efficient CTLs infiltration (Figures 7C–E). In contrast, neither the DTP-PDT nor the α-PD-L1 groups showed significant differences in T cell subpopulations (p > 0.05) relative to the model group, indicating that monotherapy was insufficient to elicit an immune response. Moreover, the proportion of Tregs (CD3+CD4+FoxP3+) in the combined treatment group significantly decreased compared to that in the model (p < 0.001) and PDT (p < 0.05) groups, confirming a reduction in tumor-associated immunosuppression (Figures 7F,G). And then the ratio of CD8+ T cells to Tregs were compared and a significant increase could be observed in Figure 7H (p < 0.01 vs. model, p < 0.05 vs. α-PD-L1 and PDT). Subsequently, immunofluorescence staining was performed on distant tumor sections to characterize the tumor immune microenvironment, Figure 7I revealed that more red fluorescence and less green fluorescence were observed in the combined therapy group, indicating the increased CD8+ T cell infiltration and decreased FoxP3+ expression. Quantitative analysis demonstrated a significant increase of CD8+/FoxP3+ ratio in the PDT + α-PD-L1 group (9.63 ± 2.91) relative to other groups (p < 0.001, Figure 7J).
3.6 Combined therapy induces systemic immune activation
Systemic immune activation was evaluated by splenic T cell redistribution. Figures 8A–C revealed DTP-PDT monotherapy elevated CD8+ and CD4+ T-cell proportions by 2.2-fold and 2.1-fold versus Model (p < 0.05). Notably, the combination therapy group showed a statistically higher CD4+ T cell proportion relative to either PDT or α-PD-L1 monotherapy. CD8+T cells proportion also increased considerably in the DTP-PDT group compared to both model and α-PD-L1 groups (p < 0.05), indicating that PDT enhances the differentiation of naive T cells into CD8+ T cells. The proportion of splenic Treg was significantly suppressed in the combined group (p < 0.001 vs. model, p < 0.01 vs. α-PD-L1 and PDT) (Figures 8D,E). Furthermore, the ratio of CD8+ T cells to Tregs was significant increased compared to other groups (Figure 7F, p < 0.05).
FIGURE 8
PDT-mediated tumor cell death induces local inflammation, accompanied by cytokine secretion, particularly TNF-α and IFN-γ (Evans et al., 1990; Zhang et al., 2022). TNF-α increased remarkably in the groups of PDT and combined therapy in comparison with the model and α-PD-L1 groups (p < 0.001, Figure 8G). TNF-α levels were significantly elevated in the combination treatment group compared to the PDT group (p < 0.05). IFN-γ was also upregulated in the combination group when compared to the other groups (p < 0.001, Figure 8H).
Collectively, these results suggested that combining DTP-PDT and α-PD-L1 therapy reshapes the immunosuppressive TME by enhancing T cell infiltration, promoting antitumor cytokine production and limiting immunosuppressive cells. This provides a strong biological foundation for the observed abscopal effects in the mTNBC model.
4 Discussion
Our study represents the first demonstration that DTP-PDT induces typical ICD features, including the surface exposure of CRT, release of HMGB1, and secretion of pro-inflammatory cytokines, all of which significantly promotes DC maturation. In a bilateral TNBC model, the synergistic treatment of DTP-PDT and α-PD-L1 substantially suppressed untreated distant tumors through systemic immune potentiation. This therapeutic effect was linked to elevated CD8+ and CD4+ T lymphocyte infiltration, and decreased proportion of Treg in both the TME and spleen.
The release of DAMPs is a critical event in ICD (Fucikova et al., 2020). Surface-translocated CRT functions as an “eat-me” signal, promoting DCs to phagocytose tumor antigens (Fucikova et al., 2020). Meanwhile, HMGB1 release activates DCs via the Toll-like receptor 4 signal pathway (Krysko et al., 2012). These events promote DC maturation (Alzeibak et al., 2021), and stimulate cytokine secretion, particularly IFN-γ and TNF-α (Andersson et al., 2000; Zhou et al., 2019), which further enhance DC function. IFN-γ enhances DC antigen presentation efficiency through major histocompatibility complex class I (MHC-I) molecules (Frucht et al., 2001; Todorović-Raković, 2022), while TNF-α further promotes DC maturation and migration capacity (Salazar-Onfray et al., 2007). Together, these cytokines may sustain and amplify DC activation, synergistically boosting the antitumor immune response initiated by DTP-PDT.
We used a bilateral 4T1 tumor model to simulate mTNBC progression. In this model, the primary tumor treated with DTP-PDT and the contralateral untreated tumor represented metastasis. Results showed minimal inhibitory effect against both primary and distant tumors in α-PD-L1 monotherapy group, validating the intrinsic immune-resistance of the 4T1 model. This resistance is primarily attributed to the low tumor mutational burden and high immunosuppressive TME of 4T1 tumor (Kim et al., 2014; Abe et al., 2016). Our analyses revealed impaired antigen presentation in 4T1 tumor model, evidenced by reduced mature DC proportions in TDLNs. Furthermore, the levels of CD4+ and CD8+ T cell infiltration in distant 4T1 tumors are low, while the proportion of Tregs is high, suggesting a dominant immunosuppressive TME. Crucially, the combination of DTP-PDT and α-PD-L1 therapy achieved significant distant tumor control. This indicates that local DTP-PDT-induced ICD can stimulate systemic antitumor immunity, eliciting an abscopal effect that inhibits metastatic lesions. This provides a potential therapeutic strategy for treating metastatic TNBC.
Immunologically, the combination therapy enhanced the maturation of DCs and overcame the inherent antigen presentation defects in TNBC. With the increase of CD8+ T cell infiltration and the decrease in the proportion of Tregs in distant tumors, the TME has shifted from an immunosuppressive “cold” state to a more immunogenic “hot” state. Notably, one of the important effector cells in the “hot” microenvironment of this transition is tumor-infiltrating lymphocytes (TILs), which contain a variety of immune system cells. Among them, the expansion of CD8+ T cells directly mediates tumor cell killing (St. Paul and Ohashi, 2020), while CD4+ T cells likely support this response (Kervevan and Chakrabarti, 2021). Tregs are the most representative immunosuppressive cells among TILs, which express the transcription factor FoxP3 and negatively regulate anticancer immunity (Kanamori et al., 2016). The reduction in Treg percentage may be partly due to the local inflammation induced by DTP-PDT, which potentially suppresses Treg differentiation. Additionally, CD8+ T cell-derived IFN-γ may further inhibits Treg function, potentially via FoxP3 downregulation. Furthermore, the ratio of CD8/Treg is a more sensitive indicator of immune function rather than evaluation of Treg or CD8+ T alone. In this study, this ratio was significantly increased in the combination therapy group and the PDT group, suggesting that these treatments induced an effective antitumor immune response and may also be associated with improved prognosis (Liu et al., 2011; Goda et al., 2022). At the systemic immunity level, the expansion of both CD8+ and CD4+ T cells, as well as a reduction in Tregs in the spleen, suggest the establishment of systemic antitumor immunity that is essential for controlling early micro-metastases in TNBC.
Collectively, the synergy between DTP-PDT and PD-L1 blockade achieves its therapeutic effect on metastatic TNBC through the following mechanism. Local tumor cell death caused by DTP-PDT results in the release of tumor associated antigens and DAMPs. These DAMPs activate infiltrating dendritic cells (DCs), promoting their phagocytosis of tumor antigens and driving their maturation and subsequent migration to tumor-draining lymph nodes. There, mature DCs present the antigens to activate naïve T cells, thereby initiating antigen-specific CD8+ cytotoxic and CD4+ helper T cell responses. PD-L1 blockade alleviates T cell exhaustion, enhancing T cell infiltration into distant tumors. The activated CD8+ T cells kill tumor cells directly, while CD4+ T cells support this process, ultimately leading to the suppression of distant tumors.
However, the present study does exist some limitations. (1) Our current findings demonstrate abscopal effect following combination therapy, we recognize the critical need to investigate the durability of these therapeutic effects. Future studies should systematically assess long-term survival outcomes, particularly the advanced recurrences after treatment and conduct tumor rechallenge experiments to the establishment of protective immune memory. (2) The 4T1 model used in this study includes key features of human TNBC metastasis, but its murine origin and tumor microenvironment differ from human pathophysiology. Future validation in patient-derived xenografts or humanized models will be essential for clinical translation.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The animal study was approved by Institutional Animal Care and Use Committee (IACUC) of the Institute of Radiation Medicine, Chinese Academy of Medical Sciences (Ethics Approval No. IRM/2-IACUC-2409-094). The study was conducted in accordance with the local legislation and institutional requirements.
Author contributions
YL: Writing – original draft, Data curation, Visualization, Methodology, Validation. LW: Methodology, Investigation, Writing – original draft, Software, Formal Analysis. FK: Writing – original draft. TL: Resources, Supervision, Writing – review and editing, Conceptualization. HL: Writing – review and editing, Conceptualization, Funding acquisition, Project administration.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by Tianjin Key Medical Discipline (Specialty) Construction Project (TJYXZDXK-009A) and CAMS Innovation Fund for Medical Sciences (2021-I2M-1-052).
Acknowledgments
We gratefully acknowledge Tianjun Liu for providing photosensitizer DTP.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AbeH.WadaH.BaghdadiM.NakanishiS.UsuiY.TsuchikawaT.et al (2016). Identification of a highly immunogenic mouse breast cancer sub cell line, 4T1-S. Hum. Cell29 (2), 58–66. 10.1007/s13577-015-0127-1
2
AgostinisP.BergK.CengelK. A.FosterT. H.GirottiA. W.GollnickS. O.et al (2011). Photodynamic therapy of cancer: an update. CA Cancer J. Clin.61 (4), 250–281. 10.3322/caac.20114
3
AkbarA.KhanS.ChatterjeeT.GhoshM. (2023). Unleashing the power of porphyrin photosensitizers: illuminating breakthroughs in photodynamic therapy. J. Photochem. Photobiol. B Biol.248, 112796. 10.1016/j.jphotobiol.2023.112796
4
AllisonR. R.HuangZ.DallimoreI.MoghissiK. (2024). Tools of clinical photodynamic therapy (PDT): a mini compendium. Photodiagnosis Photodyn. Ther.46, 104058. 10.1016/j.pdpdt.2024.104058
5
AlzeibakR.MishchenkoT. A.ShilyaginaN. Y.BalalaevaI. V.VedunovaM. V.KryskoD. V. (2021). Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. J. Immunother. Cancer9 (1), e001926. 10.1136/jitc-2020-001926
6
AnderssonU.WangH.PalmbladK.AvebergerA. C.BloomO.Erlandsson-HarrisH.et al (2000). High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med.192 (4), 565–570. 10.1084/jem.192.4.565
7
ArnautL. G. (2011). “Chapter 5 - design of porphyrin-based photosensitizers for photodynamic therapy,” in Advances in inorganic chemistry. Editors EldikR. v.StochelG. (Academic Press), 187–233.
8
AustinE.GeislerA. N.NguyenJ.KohliI.HamzaviI.LimH. W.et al (2021). Visible light. Part I: properties and cutaneous effects of visible light. J. Am. Acad. Dermatol84 (5), 1219–1231. 10.1016/j.jaad.2021.02.048
9
BhandariC.MoffatA.FakhryJ.MalkoochiA.NguyenA.TrinhB.et al (2024). A single photodynamic priming protocol augments delivery of ⍺-PD-L1 mAbs and induces immunogenic cell death in head and neck tumors. Photochem Photobiol.100 (6), 1647–1658. 10.1111/php.13865
10
BrownS. B.BrownE. A.WalkerI. (2004). The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol.5 (8), 497–508. 10.1016/S1470-2045(04)01529-3
11
ChenJ.MaoL.LiuS.LiangY.WangS.WangY.et al (2015). Effects of a novel porphyrin-based photosensitizer on sensitive and multidrug-resistant human gastric cancer cell lines. J. Photochem. Photobiol. B Biol.151, 186–193. 10.1016/j.jphotobiol.2015.08.020
12
ChenJ.WangD.WangZ.HanM.YinH.ZhouW.et al (2024). Antitumor effects of a novel photosensitizer-mediated photodynamic therapy and its influence on the cell transcriptome. Oncol. Res.32 (5), 911–923. 10.32604/or.2023.042384
13
ChenJ. J.GaoL. J.LiuT. J. (2016). Photodynamic therapy with a novel porphyrin-based photosensitizer against human gastric cancer. Oncol. Lett.11 (1), 775–781. 10.3892/ol.2015.3953
14
ChenJ.-J.LiuS.-P.ZhaoJ.WangS.-C.LiuT.-J.LiX. (2017). Effects of a novel photoactivated photosensitizer on MDR1 over-expressing human breast cancer cells. J. Photochem. Photobiol. B Biol.171, 67–74. 10.1016/j.jphotobiol.2017.04.037
15
CortesJ.CesconD. W.RugoH. S.NoweckiZ.ImS. A.YusofM. M.et al (2020). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet396 (10265), 1817–1828. 10.1016/s0140-6736(20)32531-9
16
CriscitielloC.AzimH. A.Jr.SchoutenP. C.LinnS. C.SotiriouC. (2012). Understanding the biology of triple-negative breast cancer. Ann. Oncol.23 (Suppl. 6), vi13–vi18. 10.1093/annonc/mds188
17
EvansS.MatthewsW.PerryR.FrakerD.NortonJ.PassH. I. (1990). Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J. Natl. Cancer Inst.82 (1), 34–39. 10.1093/jnci/82.1.34
18
FruchtD. M.FukaoT.BogdanC.SchindlerH.O'SheaJ. J.KoyasuS. (2001). IFN-γ production by antigen-presenting cells: mechanisms emerge. Trends Immunol.22 (10), 556–560. 10.1016/S1471-4906(01)02005-1
19
FucikovaJ.KeppO.KasikovaL.PetroniG.YamazakiT.LiuP.et al (2020). Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis.11 (11), 1013. 10.1038/s41419-020-03221-2
20
Garrido-CastroA. C.LinN. U.PolyakK. (2019). Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov.9 (2), 176–198. 10.1158/2159-8290.Cd-18-1177
21
GodaN.SasadaS.ShigematsuH.MasumotoN.ArihiroK.NishikawaH.et al (2022). The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer. Discov. Oncol.13 (1), 27. 10.1007/s12672-022-00482-5
22
HeM.ZhangM.XuT.XueS.LiD.ZhaoY.et al (2024). Enhancing photodynamic immunotherapy by reprograming the immunosuppressive tumor microenvironment with hypoxia relief. J. Control Release368, 233–250. 10.1016/j.jconrel.2024.02.030
23
KanamoriM.NakatsukasaH.OkadaM.LuQ.YoshimuraA. (2016). Induced regulatory T cells: their development, stability, and applications. Trends Immunol.37 (11), 803–811. 10.1016/j.it.2016.08.012
24
KennedyL. B.SalamaA. K. S. (2020). A review of cancer immunotherapy toxicity. CA Cancer J. Clin.70 (2), 86–104. 10.3322/caac.21596
25
KervevanJ.ChakrabartiL. A. (2021). Role of CD4+ T cells in the control of viral infections: recent advances and open questions. Int. J. Mol. Sci.22 (2), 523. 10.3390/ijms22020523
26
KhosraviG. R.MostafaviS.BastanS.EbrahimiN.GharibvandR. S.EskandariN. (2024). Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. (Lond)44 (5), 521–553. 10.1002/cac2.12539
27
KimK.SkoraA. D.LiZ.LiuQ.TamA. J.BlosserR. L.et al (2014). Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc. Natl. Acad. Sci. U. S. A.111 (32), 11774–11779. 10.1073/pnas.1410626111
28
KryskoD. V.GargA. D.KaczmarekA.KryskoO.AgostinisP.VandenabeeleP. (2012). Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer12 (12), 860–875. 10.1038/nrc3380
29
Leon-FerreR. A.GoetzM. P. (2023). Advances in systemic therapies for triple negative breast cancer. Bmj381, e071674. 10.1136/bmj-2022-071674
30
LiL.XuQ.ZhangX.JiangY.ZhangL.GuoJ.et al (2025). AIEgen-self-assembled nanoparticles with anti-PD-L1 antibody functionalization realize enhanced synergistic photodynamic therapy and immunotherapy against malignant melanoma. Mater Today Bio30, 101387. 10.1016/j.mtbio.2024.101387
31
LiY.ZhangH.MerkherY.ChenL.LiuN.LeonovS.et al (2022a). Recent advances in therapeutic strategies for triple-negative breast cancer. J. Hematol. Oncol.15 (1), 121. 10.1186/s13045-022-01341-0
32
LiZ.LaiX.FuS.RenL.CaiH.ZhangH.et al (2022b). Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv. Sci. (Weinh)9 (22), e2201734. 10.1002/advs.202201734
33
LiuF.LangR.ZhaoJ.ZhangX.PringleG. A.FanY.et al (2011). CD8+ cytotoxic T cell and FOXP3+ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res. Treat.130 (2), 645–655. 10.1007/s10549-011-1647-3
34
LiuY.HuY.XueJ.LiJ.YiJ.BuJ.et al (2023). Advances in immunotherapy for triple-negative breast cancer. Mol. Cancer22 (1), 145. 10.1186/s12943-023-01850-7
35
LoboC. S.MendesM. I. P.PereiraD. A.Gomes-da-SilvaL. C.ArnautL. G. (2023). Photodynamic therapy changes tumour immunogenicity and promotes immune-checkpoint blockade response, particularly when combined with micromechanical priming. Sci. Rep.13 (1), 11667. 10.1038/s41598-023-38862-8
36
McMorrowR.de BruijnH. S.FarinaS.van ArdenneR. J. L.QueI.MastroberardinoP. G.et al (2025). Combination of bremachlorin PDT and immune checkpoint inhibitor Anti-PD-1 shows response in murine immunological T-cell-High and T-cell-Low PDAC models. Mol. Cancer Ther.24 (4), 605–617. 10.1158/1535-7163.Mct-23-0733
37
Meric-BernstamF.LarkinJ.TaberneroJ.BoniniC. (2021). Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet397 (10278), 1010–1022. 10.1016/S0140-6736(20)32598-8
38
PhamT. C.NguyenV. N.ChoiY.LeeS.YoonJ. (2021). Recent strategies to develop innovative photosensitizers for enhanced photodynamic therapy. Chem. Rev.121 (21), 13454–13619. 10.1021/acs.chemrev.1c00381
39
Salazar-OnfrayF.LópezM. N.Mendoza-NaranjoA. (2007). Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev.18 (1-2), 171–182. 10.1016/j.cytogfr.2007.01.015
40
SchmidP.AdamsS.RugoH. S.SchneeweissA.BarriosC. H.IwataH.et al (2018). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med.379 (22), 2108–2121. 10.1056/NEJMoa1809615
41
St. PaulM.OhashiP. S. (2020). The roles of CD8+ T cell subsets in antitumor immunity. Trends Cell Biol.30 (9), 695–704. 10.1016/j.tcb.2020.06.003
42
SubhanM. A. (2024). “Triple-negative breast cancer therapy: recent advances, challenges, and future perspective,” in Breast cancer treatment: an interdisciplinary approach. Editor RezaeiN. (Cham: Springer Nature Switzerland), 27–44.
43
TianJ.HuangB.NawazM. H.ZhangW. (2020). Recent advances of multi-dimensional porphyrin-based functional materials in photodynamic therapy. Coord. Chem. Rev.420, 213410. 10.1016/j.ccr.2020.213410
44
Todorović-RakovićN. (2022). The role of cytokines in the evolution of cancer: IFN-γ paradigm. Cytokine151, 155442. 10.1016/j.cyto.2021.155442
45
YinW. H.LiP. Y.HuangH. H.FengL.LiuS. H.LiuX.et al (2024). Porphyrin photosensitizer molecules as effective medicine candidates for photodynamic therapy: electronic structure information aided design. RSC Adv.14 (40), 29368–29383. 10.1039/d4ra05585c
46
YuY.XuB.XiangL.DingT.WangN.YuR.et al (2023). Photodynamic therapy improves the outcome of immune checkpoint inhibitors via remodelling anti-tumour immunity in patients with gastric cancer. Gastric Cancer26 (5), 798–813. 10.1007/s10120-023-01409-x
47
ZhangM.ZhaoY.MaH.SunY.CaoJ. (2022). How to improve photodynamic therapy-induced antitumor immunity for cancer treatment?Theranostics12 (10), 4629–4655. 10.7150/thno.72465
48
ZhaoM.HaoD.WuQ.LiY.PeiQ.SunT.et al (2023). Porphyrin cholesterol conjugates for enhanced photodynamic immunotherapy toward lung cancer. ACS Appl. Mater Interfaces15 (30), 35927–35938. 10.1021/acsami.3c05825
49
ZhouJ.WangG.ChenY.WangH.HuaY.CaiZ. (2019). Immunogenic cell death in cancer therapy: present and emerging inducers. J. Cell. Mol. Med.23 (8), 4854–4865. 10.1111/jcmm.14356
50
ZhuS.WuY.SongB.YiM.YanY.MeiQ.et al (2023). Recent advances in targeted strategies for triple-negative breast cancer. J. Hematol. Oncol.16 (1), 100. 10.1186/s13045-023-01497-3
51
ZhuS.ZhangT.ZhengL.LiuH.SongW.LiuD.et al (2021). Combination strategies to maximize the benefits of cancer immunotherapy. J. Hematol. Oncol.14 (1), 156. 10.1186/s13045-021-01164-5
Summary
Keywords
photodynamic therapy, immunogenic cell death, metastatic triple-negative breast cancer, programmed death-ligand 1 blockade, abscopal effect, systemic antitumor immunity
Citation
Liu Y, Wang L, Kong F, Liu T and Liu H (2025) An immunomodulatory photosensitizer-mediated photodynamic therapy synergizes with PD-L1 blockade against metastatic triple-negative breast cancer. Front. Pharmacol. 16:1651165. doi: 10.3389/fphar.2025.1651165
Received
21 June 2025
Accepted
08 July 2025
Published
17 July 2025
Volume
16 - 2025
Edited by
Tingting Zhao, China-Japan Friendship Hospital, China
Reviewed by
Guoliang Dai, Affiliated Hospital of Nanjing University of Chinese Medicine, China
Yiqi Xu, Hong Kong Baptist University, Hong Kong SAR, China
Updates
Copyright
© 2025 Liu, Wang, Kong, Liu and Liu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tianjun Liu, liutj@bme.pumc.edu.cn; Hong Liu, liuhong_submit@tjmuch.com
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.